Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience

Figure 1

At clinical examination, presence of necrotic bone exposure (a) classified as stage III MRONJ depending on the dimensional staging system on the right maxilla in a female 67-year-old patient affected by breast cancer, who underwent denosumab administration 11 times. Rx OPT shows bone support reduction on the right maxilla. Patient referred the spontaneous loss of 4 teeth (1.7, 1.6, 1.3, and 1.2) after she underwent the orthopantomography, probably due to the progressive bone necrosis and resorption (b). After 16-month follow-up, clinical (c) and radiological (d) healing of the patient who underwent a removable prosthetic restoration (e-f).

(a)

(b)

(c)

(d)

(e)

(f)